|
Sareum Holdings PLC on Tuesday reported a strategic collaboration with AI-driven drug discovery firm, Receptor.AI, as it looks to accelerate the identification of high-potential candidates for neuroinflammatory conditions. Sareum is a Cambridge, England-based pharmaceutical company focused on developing next-generation kinase inhibitors for autoimmune disease and cancer. Receptor.AI is a Cambridge, Massachusetts-based AI drug discovery company designing novel drug modalities. The partnership aims to generate high-quality candidates suitable for preclinical development in neuroinflammatory indications, said Sareum, such as Parkinson’s or multiple sclerosis. Sareum said the collaboration will focus on driving the ‘discovery and optimisation of blood-brain barrier (BBB)-permeable, isoform-selective TYK2/JAK1 inhibitors.’ Shares in Sareum climbed 15% to 18.95 pence on Tuesday afternoon in London. Under the terms of the partnership, Sareum is set to oversee compound synthesis, laboratory testing and ‘profiling of absorption, distribution, metabolism, excretion, and toxicity’ in order to evaluate the behaviour of potential drug candidates. Receptor.AI will contribute through the utilisation of its AI-enabled platform to support compound discovery and optimisation, noted Sareum. It added that it will use virtual screening and molecular design tools to identify candidates with ‘strong target binding, brain penetration, selectivity, and synthetic feasibility.’ Sareum anticipates the project commencing ‘imminently’, with it expected to be completed within four months. It added that it will own the IP and compounds resulting from the partnership, with ongoing milestone payments due to Receptor.AI post project conclusion. ‘This collaboration is a logical and timely next step following our recent findings on BBB-penetrant TYK2/JAK1 inhibitors. Receptor.AI’s expertise in integrating predictive modelling and generative chemistry into the discovery process will help us accelerate the identification of high-potential candidates for neuroinflammatory conditions,’ said Sareum Executive Chair Stephen Parker. ‘This technology allows us to harness the speed and accuracy of AI to derisk and optimise our discovery and early development,’ continued Parker. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
